HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus

Files in This Item:
63_EJ16-0266.pdf823.14 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/68407

Title: Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus
Authors: Koyanagawa, Naohide Browse this author
Miyoshi, Hideaki Browse this author →KAKEN DB
Ono, Kota Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Cho, Kyu Yong Browse this author
Yamamoto, Kohei Browse this author
Takano, Yoshinari Browse this author
Dan-Noura, Midori Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Keywords: Vildagliptin
Sitagliptin
Mean amplitude of glycemic excursions (MAGE)
Issue Date: Aug-2016
Publisher: The Japan Endocrine Society
Journal Title: Endocrine Journal
Volume: 63
Issue: 8
Start Page: 747
End Page: 753
Publisher DOI: 10.1507/endocrj.EJ16-0266
PMID: 27321385
Abstract: The dipeptidyl peptidase-4 inhibitors vildagliptin and sitagliptin are effective in treating patients with type 2 diabetes mellitus. Patients receiving standard doses of sitagliptin plus insulin may require increased doses of sitagliptin or switching to vildagliptin to improve blood glucose control. This study compared the effects of increasing sitagliptin and switching to vildagliptin in type 2 diabetes patients receiving standard doses of sitagliptin plus insulin. This prospective, randomized, parallel-group comparison trial enrolled 33 type 2 diabetes patients receiving 50 mg sitagliptin once daily plus insulin. Seventeen patients were randomized to 50 mg vildagliptin twice daily, and 16 to 100 mg sitagliptin once daily, and evaluated by continuous glucose monitoring at baseline and after 8 weeks. The primary end-point was the change in mean amplitude of glycemic excursions (MAGE). MAGE decreased from baseline in both the vildagliptin (-13.4 ± 35.7 mg/dL) and sitagliptin (-8.4 ± 24.3 mg/dL) groups, but neither within- nor between-group changes were statistically significant. Similarly, the areas under the curve for blood glucose levels ≥180 mg/dL and <70 mg/dL tended to improve in both groups, but these differences were not statistically significant. In contrast, HbA1c was significantly reduced only in the vildagliptin group, from 7.1 ± 0.6% at baseline to 6.8 ± 0.6% at 8 weeks (p=0.006). Increasing sitagliptin dose and switching to vildagliptin had limited effects in improving MAGE in type 2 diabetic patients treated with standard doses of sitagliptin.
Type: article
URI: http://hdl.handle.net/2115/68407
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University